Why These 15 Stocks Are Skyrocketing in 2025

11. Adaptive Biotechnologies (NASDAQ:ADPT)

Number of Hedge Fund Holders In Q3 2024: 19

Adaptive Biotechnologies (NASDAQ:ADPT) is a biotech company that makes immune medicine products. It focuses on Minimal Residual Disease (MRD) and Immune Medicine. The first is an FDA-cleared clonoSEQ test for cancer treatment response monitoring, and the second one uses immune receptor data for drug discovery and clinical trials.

The recent bullishness is due to the Centers for Medicare & Medicaid Services setting a favorable reimbursement rate of $2,007 for the company’s clonoSEQ test. It also announced a collaboration with NeoGenomics to expand access to MRD testing for blood cancer patients.

Adaptive also reported strong growth in its MRD business, with revenue growing 52% year-over-year in Q3 2024. The cost optimization focus also reduced its net loss by 36%.

The consensus price target of $8 implies 0.12% downside.

The stock is up 29.4% year-to-date.